Alopecia areata xeljanz?

Short answer: Xeljanz (tofacitinib) is a JAK inhibitor that has shown some promise for alopecia areata in small studies and case reports, but it is not officially approved by the FDA for alopecia areata. Some other JAK inhibitors (like baricitinib) have received approval for alopecia areata in adults in some places. If you’re considering this, it should be under a doctor’s care because of safety considerations.

What’s known about tofacitinib for alopecia areata
- How it works: Tofacitinib blocks certain inflammatory pathways (JAK pathways) thought to be involved in alopecia areata.
- Evidence so far: Small studies and case reports have reported hair regrowth in some people with patchy alopecia areata. Results vary, and many patients relapse after stopping the drug.
- Not FDA-approved for AA: As of 2024, it is used for other conditions (like rheumatoid arthritis) but not officially approved for alopecia areata. Dosing used in AA cases is usually off-label.

Common dosing that has been used in AA (under a clinician’s supervision)
- Typical starting point around 5 mg twice daily (some patients have used 2.5 mg twice daily or other regimens). Dosing is individualized and higher doses tend to carry more safety concerns.
- If there’s a response, the doctor may adjust the dose or discontinue if hair regrowth stabilizes. Stopping often leads to regrowth loss again in AA.

Safety and monitoring (important)
- Infections: Higher risk of serious infections, including shingles/herpes and others. Screen for latent infections (e.g., tuberculosis) before starting.
- Blood tests and labs: Regular monitoring of complete blood count, liver enzymes, kidney function, and lipids is common.
- Lipids and cardiovascular risk: Potential increases in cholesterol; discuss risk factors with your doctor.
- Cancer risk: There is a general warning about malignancies with JAK inhibitors; discuss personal risk factors.
- Pregnancy and breastfeeding: Generally advised against; use effective contraception. Talk to your doctor if you’re planning pregnancy.
- Vaccinations: Live vaccines are usually avoided while taking JAK inhibitors; discuss vaccines with your clinician.
- Other considerations: Not everyone tolerates it well; interactions with other medicines (including some supplements) can occur.

Practical steps if you’re considering this
- Talk with a dermatologist or rheumatologist about whether a JAK inhibitor is appropriate for your AA, your medical history, and your current medications.
- Discuss baseline tests and monitoring plan (blood work, TB/hepatitis screening, lipid panel, etc.).
- Review safety concerns and what to watch for (infection signs, unusual bleeding, severe headache, chest pain, etc.).
- Have a plan for what to do if you don’t see improvement or if hair loss returns after stopping.

If you’d like, tell me:
- Are you considering this for yourself or someone else?
- Do you have other health conditions or medications that might affect safety?
- Are you looking for information on how it compares with other treatments (like topical therapies, intralesional steroids, or other JAK inhibitors such as baricitinib)?

I can tailor the info to your situation and also summarize pros/cons or the latest trial findings.